Risk of cerebral venous thrombosis in obese women

JAMA Neurology

Volumn 73, Issue 5, 2016, Pages 579-584

  Zuurbier, Susanna M ^a   Arnold, Marcel ^b   Middeldorp, Saskia ^a   Broeg Morvay, Anne ^b   Silvis, Suzanne M ^a   Heldner, Mirjam R ^b   Meisterernst, Julia ^b   Nemeth, Banne ^c   Meulendijks, Eva R ^a   Stam, Jan ^a   Cannegieter, Suzanne C ^c   Coutinho, Jonathan M ^a,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGE DISTRIBUTION; ARTICLE; BODY MASS; BRAIN EDEMA; BRAIN HEMORRHAGE; CAUCASIAN; CEREBRAL SINUS THROMBOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ETHNICITY; FEMALE; FEMALE BY SEXUAL ORIENTATION; HEADACHE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NETHERLANDS; NEUROLOGIC DISEASE; OBESITY; ORAL CONTRACEPTIVE USE; PAPILLEDEMA; PATIENT HISTORY OF CANCER; PRIORITY JOURNAL; RISK FACTOR; SEIZURE; SMOKING; SWITZERLAND; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; INTRACRANIAL THROMBOSIS; MIDDLE AGED; ODDS RATIO; SEX DIFFERENCE; VENOUS THROMBOSIS;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; INTRACRANIAL THROMBOSIS; MIDDLE AGED; OBESITY; ODDS RATIO; RISK FACTORS; SEX FACTORS; VENOUS THROMBOSIS;

EID: 84966671866     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.0001     Document Type: Article

References (44)

1. Brækkan SK, Hald EM, Mathiesen EB, et al. Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study. Arterioscler Thromb Vasc Biol. 2012;32(2):487-491.
2. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162(10):1182-1189.
3. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010;121 (17):1896-1903.
4. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007;139 (2):289-296.
5. Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjønneland A, Overvad K. Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study. Circulation. 2009;120(19):1850-1857.
6. Parkin L, Sweetland S, Balkwill A, Green J, Reeves G, Beral V; Million Women Study Collaborators. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation. 2012;125(15):1897-1904.
7. Zuurbier SM, van den Berg R, Troost D, Majoie CB, Stam J, Coutinho JM. Hydrocephalus in cerebral venous thrombosis. J Neurol. 2015;262(4):931-937.
8. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791-1798.
9. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP; The Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. BMJ. 1998; 316(7131):589-592.
10. Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx GJ. Risk factors for cerebral venous thrombosis and deep venous thrombosis in patients aged between 15 and 50 years. Thromb Haemost. 2009;102(4):620-622.
11. Zuurbier SM, Lauw MN, Coutinho JM, et al. Clinical course of cerebral venous thrombosis in adult acute lymphoblastic leukemia. J Stroke Cerebrovasc Dis. 2015;24(7):1679-1684.
12. Pearson V, Ruzas C, Krebs NF, Goldenberg NA, Manco-Johnson MJ, Bernard TJ. Overweight and obesity are increased in childhood-onset cerebrovascular disease. J Child Neurol. 2013;28(4): 517-519.
13. de Veber G, Andrew M, Adams C, et al; Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children. N Engl J Med. 2001;345(6):417-423.
14. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158-1192.
15. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6): 715-722.
16. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006;59(10):1087-1091.
17. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89(3): 493-498.
18. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33(5): 1202-1208.
19. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277(8):642-645.
20. Bonita R, Beaglehole R, Kjellstrom T. Environmental and Occupational Epidemiology: Basic Epidemiology. 2nd ed. Geneva, Switzerland: World Health Organization; 2006:93-95.
21. De Pergola G, De Mitrio V, Giorgino F, et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord. 1997;21(7):527-535.
22. Christiansen SC, Lijfering WM, Naess IA, et al. The relationship between body mass index, activated protein C resistance and risk of venous thrombosis. J Thromb Haemost. 2012;10(9):1761-1767.
23. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet. 1999;354(9195): 2036-2040.
24. Schokker DF, Visscher TL, Nooyens AC, van Baak MA, Seidell JC. Prevalence of overweight and obesity in the Netherlands. Obes Rev. 2007;8 (2):101-108.
25. Wall M, Kupersmith MJ, Kieburtz KD, et al; NORDIC Idiopathic Intracranial Hypertension Study Group. The Idiopathic Intracranial Hypertension Treatment Trial: clinical profile at baseline. JAMA Neurol. 2014;71(6):693-701.
26. Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology. 1999;53 (7):1537-1542.
27. Leker RR, Steiner I. Features of dural sinus thrombosis simulating pseudotumor cerebri. Eur J Neurol. 1999;6(5):601-604.
28. Kesler A, Goldhammer Y, Gadoth N. Do men with pseudomotor cerebri share the same characteristics as women? a retrospective review of 141 cases. J Neuroophthalmol. 2001;21(1):15-17.
29. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664-670.
30. Balcer LJ, Liu GT, Forman S, et al. Idiopathic intracranial hypertension: relation of age and obesity in children. Neurology. 1999;52(4):870-872.
31. Nedelmann M, Kaps M, Mueller-Forell W. Venous obstruction and jugular valve insufficiency in idiopathic intracranial hypertension. J Neurol. 2009;256(6):964-969.
32. Wakerley BR, Tan MH, Ting EY. Idiopathic intracranial hypertension. Cephalalgia. 2015;35(3): 248-261.
33. Sugerman HJ, DeMaria EJ, Felton WL III, Nakatsuka M, Sismanis A. Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Neurology. 1997;49(2):507-511.
34. Rohr A, Dörner L, Stingele R, Buhl R, Alfke K, Jansen O. Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR Am J Neuroradiol. 2007;28(4):656-659.
35. Puffer RC, Mustafa W, Lanzino G. Venous sinus stenting for idiopathic intracranial hypertension: a review of the literature. J Neurointerv Surg. 2013;5 (5):483-486.
36. Piper RJ, Kalyvas AV, Young AM, Hughes MA, Jamjoom AA, Fouyas IP. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2015;8:CD003434.
37. Clinical Trials.gov. Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy (VSSIIH). NCT01407809. https://clinicaltrials.gov/ct2/show/NCT01407809. Accessed December 1, 2015.
38. Clinical Trials.gov. Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension. NCT02143258. https://clinicaltrials.gov/ct2/show/NCT02143258. Accessed December 1, 2015.
39. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998; 338(25):1793-1797.
40. Moons KG, Donders RA, Stijnen T, Harrell FE Jr. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol. 2006;59(10):1092-1101.
41. Chou KT, Huang CC, Chen YM, et al. Sleep apnea and risk of deep vein thrombosis: a non-randomized, pair-matched cohort study. Am J Med. 2012;125(4):374-380.
42. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014;383(9918): 736-747.
43. Middeldorp S. Thrombosis in women: what are the knowledge gaps in 2013? J Thromb Haemost. 2013;11(suppl 1):180-191.
44. van Vlijmen EF, Veeger NJ, Middeldorp S, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood. 2011;118(8):2055-2061.